Pediatric Allergy: An Overview
Prim Care. 2021 Sep;48(3):517-530. doi: 10.1016/j.pop.2021.04.006. Epub 2021 Jul 10.ABSTRACTAllergy is a broad topic encompassing common clinical allergic diseases, asthma, and complex immunodeficiencies. In this article, the authors discuss the most common allergic diseases and anaphylaxis and briefly review the current knowledge and management of food allergies, allergic rhinitis, otitis media, sinusitis, chronic cough, atopic dermatitis, urticarial and angioedema, contact dermatitis, allergic ophthalmopathy, drug allergy, latex allergy, and insect sting. Because the prevalence of allergic disorders continues to increase, it is increasingly important for physicians to stay up to date on most recent evidence-based diagnosis and management of allergic disorders.PMID:34311855 | DOI:10.1016/j.pop.2021.04.006
ConclusionsTechnology has the capability of transforming the use of patient-reported outcomes. Describing all the development phases of a mobile health application for monitoring children and adolescents with asthma may increase the knowledge on how to design applications for young patients.
Targeted testing of individuals with a range of signs and symptoms could improve diagnosis of coeliac disease, a new National Institute for Health Research (NIHR) funded study led by the University of Bristol and published in PLOS ONE has found. Signs and symptoms include family history of coeliac disease, dermatitis herpetiformis, anaemia, type 1 diabetes, osteoporosis and chronic liver disease.
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to...
Condition: Atopic Dermatitis Interventions: Other: Audio recordings during the consultations; Other: Audio recordings during the consultations and test of the shared medical decision-making tool for modification; Other: Audio recordings during the consultations and test of the shared medical decision-making tool for validation Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting
Condition: Atopic Dermatitis Intervention: Genetic: DNA analysis Sponsor: Asfendiyarov Kazakh National Medical University Not yet recruiting
Condition: Asthma Interventions: Behavioral: Controlling Asthma Program for Adolescents (CAMP Air); Behavioral: Attention Control Asthma Education Intervention Sponsors: Columbia University; 3-C Institute for Social Development; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Conditions: Staphylococcus Aureus; Atopic Dermatitis Intervention: Device: Natural Lactic Acid-enriched Cream Sponsor: Microbio Co Ltd Not yet recruiting
Conditions: Whooping Cough; Diphtheria; Tetanus Interventions: Biological: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed; Biological: Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed; Biological: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed ) and Haemophilus influenzae type b conjugate vaccine Sponsors: China National Biotec Group Company Limited; Beijing Institute of Biological Products Co Ltd. Not yet recruiting
Conditions: Depression; Tuberculosis Interventions: Behavioral: Interpersonal Counseling; Behavioral: Enhanced treatment as usual Sponsors: New York State Psychiatric Institute; Columbia University; Desmond Tutu HIV Foundation; University of Cape Town; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Condition: Asthma; Eosinophilic Intervention: Biological: Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019 Sponsors: Medical University of Lodz; GlaxoSmithKline Not yet recruiting